← Back to headlines
Novo Nordisk Shares Plunge After Obesity Drug Fails to Outperform Zepbound
Novo Nordisk's shares dropped significantly after its new obesity drug did not demonstrate superior efficacy compared to Zepbound.
23 Feb, 16:44 — 23 Feb, 16:44
ℹOnly 1 source covers this story
